Abstract:BACKGROUND:Recent studies show that mutations in Leucine Rich Repeat Kinase 2 (LRRK2) are the cause of the most common inherited and some sporadic forms of Parkinson's disease (PD). The molecular mechanism underlying the pathogenic role of LRRK2 mutations in PD remains unknown.METHODOLOGY/PRINCIPAL FINDINGS:Using affinity purification and mass spectrometric analysis, we investigated phosphorylation sites and binding proteins of LRRK2 purified from mouse brain. We identified multiple phosphorylation sites at N-terminus of LRRK2 including S910, S912, S935 and S973. Focusing on the high stoichiometry S935 phosphorylation site, we developed an anti-pS935 specific antibody and showed that LRRK2 is constitutively phosphorylated at S935 in various tissues (including brain) and at different ages in mice. We find that 14-3-3 proteins (especially isoforms γ and η) bind LRRK2 and this binding depends on phosphorylation of S935. The binding of 14-3-3, with little effect on dimer formation of LRRK2, confers protection of the phosphorylation status of S935. Furthermore, we show that protein kinase A (PKA), but not LRRK2 kinase itself, can cause the phosphorylation of LRRK2 at S935 in vitro and in cell culture, suggesting that PKA is a potential upstream kinase that regulates LRRK2 function. Finally, our study indicates that the common PD-related mutations of LRRK2, R1441G, Y1699C and G2019S, decrease homeostatic phosphorylation levels of S935 and impair 14-3-3 binding of LRRK2.CONCLUSIONS/SIGNIFICANCE:LRRK2 is extensively phosphorylated in vivo, and the phosphorylation of specific sites (e.g. S935) determines 14-3-3 binding of LRRK2. We propose that 14-3-3 is an important regulator of LRRK2-mediated cellular functions. Our study suggests that PKA, a cAMP-dependent kinase involved in regulating dopamine physiology, is a potential upstream kinase that phosphorylates LRRK2 at S935. Furthermore, the reduction of phosphorylation/14-3-3 binding of LRRK2 due to the common familial PD-related mutations provides novel insight into the pathogenic mechanism of LRRK2-linked PD.

Correlation between Mutations in the LRRK2 and Parkinson′s Disease

The Role of the LRRK2 Gene in Parkinsonism

Advance of the Study on LRRK2 Gene in Parkinson's Disease

Clinical and Functional Evidence for the Pathogenicity of the LRRK2 P.arg1067gln Variant

Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease

Correlation between LRRK2 gene polymorphism sites S1647T and R1398H and Parkinson's disease in a Chinese Han population

Clinical Features and Mutation Analysis of LRRK2 Gene in Patients with Autosomal Dominant Familial Parkinson's Disease

The LRRK2 gene is mutated in a Chinese autosomal-dominant Parkinson's disease family.

Mouse models for LRRK2 Parkinson's disease.

Correlation between leucine-rich repeat kinase 2 and glucocerebrosidase gene gene polymorphisms and Parkinson disease

Genetic Analysis of LRRK2 in Parkinson's Disease in Han Chinese Population.

The Heterozygous R1441C Mutation of Leucine-Rich Repeat Kinase 2 Gene in a Chinese Patient with Parkinson Disease: A Five-Year Follow-Up and Literatures Review

Leucine-rich Repeat Kinase 2 (LRRK2) Interacts with Parkin, and Mutant LRRK2 Induces Neuronal Degeneration

The Parkinson's Disease-Associated Mutation LRRK2 G2385R Alters Mitochondrial Biogenesis Via the PGC-1α-TFAM Pathway.

LRRK2, a puzzling protein: Insights into Parkinson's disease pathogenesis

How Parkinson's Disease-Linked LRRK2 Mutations Affect Different CNS Cell Types

Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease.

Analysis of Rare Variants of Autosomal‐dominant Genes in a Chinese Population with Sporadic Parkinson’s Disease

Phosphorylation-dependent 14-3-3 Binding to LRRK2 is Impaired by Common Mutations of Familial Parkinson's Disease.

Kinase Activity of Mutant LRRK2 Mediates Neuronal Toxicity

Expression Profiling and Localization Analysis of Parkinson's Disease Associated Protein LRRK2